Is the rs1801282 (G/C) Polymorphism of PPAR - Gamma Gene Associated with T2DM in Iraqi People?
DOI:
https://doi.org/10.3889/oamjms.2018.156Keywords:
PPAR gamma, T2DM, polymorphism, Pro12Ala, IraqiAbstract
BACKGROUND: Pro12Ala (rs1801282) is a common polymorphism of the human PPAR-γ gene. Studies have demonstrated conflicting results about its association with T2DM worldwide. There are no reports about such possible association among Iraqi people.Â
OBJECTIVES: Â This study aims at finding out whether having the mutant allele (Ala12) might be associated with T2DM among Iraqi people.
METHODS: One hundred and ninety-two Arabic Iraqi adult subjects (97 with T2DM and 95 controls) were genotyped using PCR- RFLP. Clinical, anthropometrical and biochemical variables were compared regarding the Pro12Ala genotypes.
RESULTS: About 5.67% of people with diabetes were carriers of the (Ala12) allele versus 9.47% of controls. Allelic and genotypic frequencies were not statistically different among diabetics and controls [(c2= 1.99, p= 0.16) and (c2= 2.17, p= 0.14)]. Age, BMI and smoking- but not Pro12Ala - were independent risk factors for T2DM in our subjects. Pro12Ala was not associated with T2DM (Odd's ratio 0.55, 95% CI 0.23- 1.32, p= 0.14).
CONCLUSIONS: Our study revealed a relatively high frequency of the Ala12 allele among Arabic Iraqis. These frequencies did not significantly differ between diabetics and controls indicating the absence of association of Pro12Ala with T2DM among Iraqis.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Barnett PS and Braunstein GD. Diabetes Mellitus. In: Carpenter CCJ, Griggs RC, Benjamin IJ (Eds). Andreoli and Carpenter's Cecil Essentials of Medicine, 7th. ed., Saunders Elsevier, Philadelphia, USA, 2007: pp 676- 707.
Knowler WC, Pettitt DJ, Saad MF, Bennett PH. Diabetes mellitus in the Pima Indians: incidence, risk factors and pathogenesis. Diab Metab Rev. 1990; 6: 1-27. https://doi.org/10.1002/dmr.5610060101
Florez JC, Hirschhorn, Altshuler D. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Ann Rev Ge nomics Hum Genet. 2003; 4: 257- 291. https://doi.org/10.1146/annurev.genom.4.070802.110436 PMid:14527304
Freeman H and Cox RD. Type-2 diabetes: a cocktail of genetic discovery. Hum Mol Genet. 2006; 15 (2): R 202- 209.
The International HapMap Consortium. The International HapMap Project. Nature. 2003; 426 (6968): 789–796. https://doi.org/10.1038/nature02168 PMid:14685227
The International HapMap Consortium. A haplotype map of the human genome. Nature. 2005; 437 (7063): 1299–1320. https://doi.org/10.1038/nature04226 PMid:16255080 PMCid:PMC1880871
Fareed M, Afzal M. Single nucleotide polymorphism in genome- wide association of human population: A tool for broad spectrum services. Egyp J Med Hum Genet. 2013; 14: 123- 134. https://doi.org/10.1016/j.ejmhg.2012.08.001
Clarke GM, Anderson CA, Pettersson FH, et al. Basic statistical analysis in genetic case- control studies. Nat Protoc. 2011; 6(2): 121- 133. https://doi.org/10.1038/nprot.2010.182 PMid:21293453 PMCid:PMC3154648
Schwanstecher C and Schwanstecher M. Nucleotide sensitivity of pancreatic ATP-sensitive potassium channels and type 2 diabetes. Diabetes. 2002; 51(Suppl.3): S358- S362. https://doi.org/10.2337/diabetes.51.2007.S358 PMid:12475775
Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPAR γ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999; 402 (6764): 880- 883. https://doi.org/10.1038/47254 PMid:10622252
Simonis-Bik AM, Nijpels G, Van Haeften TW, et al. Gene variants in the novel Type 2 diabetes loci CDC123/CAMK1D, THADA, ADAMTS9, BCL11A, and MTNR1B affect different aspects of pancreatic β-cell function. Diabetes. 2010; 59: 293- 301. https://doi.org/10.2337/db09-1048 PMid:19833888 PMCid:PMC2797936
Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell. 1995; 83(6): 835-839. https://doi.org/10.1016/0092-8674(95)90199-X
Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 1996; 37(5): 907-925. PMid:8725145
Perissi V and Rosenfeld MG. Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol. 2005; 6(7): 542- 554. https://doi.org/10.1038/nrm1680 PMid:15957004
Tachibana K, Kobayashi Y, Tanaka T, et al. Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing PPAR isoforms. Nuclear Receptor. 2005; 3:1–17. https://doi.org/10.1186/1478-1336-3-3 PMid:16197558 PMCid:PMC1262764
He W. PPARgamma2 Polymorphism and Human Health. PPAR Res. 2009; 2009:849538. https://doi.org/10.1155/2009/849538
PMid:19390629 PMCid:PMC2669649
Stumvoll M and Häring H. The peroxisome proliferator- activated receptor- γ2 Prol 12 Ala polymorphism. Diabetes. 2002; 51(8): 2341- 2347. https://doi.org/10.2337/diabetes.51.8.2341 PMid:12145143
Olefsky JM. Treatment of insulin resistance with peroxisome proliferator- activated receptor γ agonists. J Clin Invest. 2000; 106(4): 467- 472. https://doi.org/10.1172/JCI10843 PMid:10953021 PMCid:PMC380259
Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nature Medicine. 2004; 10(4): 355- 361. https://doi.org/10.1038/nm1025 PMid:15057233
Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator- activated receptor –γ2 on thiazolidinedion- induced adipogenesis. BBRC. 2000; 268(1): 178- 182. PMid:10652233
Yen CJ, Beamer BA, Negri C, et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun. 1997; 241: 270-274. https://doi.org/10.1006/bbrc.1997.7798 PMid:9425261
Gouda HN, Sagoo GS, Harding AH, et al. The association between the peroxisome proliferator- activated receptor-γ2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: A HuGE review and meta- analysis. Am J Epidemiol. 2010; 171: 645- 655. https://doi.org/10.1093/aje/kwp450 PMid:20179158 PMCid:PMC2834889
Srámková D, Kunesová M, Hainer V, et al. Is a Pro12Ala polymorphism of the PPARgamma 2 gene related to obesity and type 2 diabetes mellitus in the Czech population? Ann N Y Acad Sci. 2002; 967: 265- 273. https://doi.org/10.1111/j.1749-6632.2002.tb04282.x PMid:12079854
Muller YL, Bogardus C, Beamer BA, Shuldiner AR, Baier LJ. A functional variant in the peroxisome proliferator-activated receptor γ2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians. Diabetes. 2003; 52 (7): 1864-1871. https://doi.org/10.2337/diabetes.52.7.1864 PMid:12829658
Doney ASF, Fischer B, Cecil JE, et al. Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes. Diabetologia. 2004; 47(3): 555-558. https://doi.org/10.1007/s00125-003-1323-1 PMid:14730381
Zouari Bouassida K, Chouchane L, Jellouli K, et al. The peroxisome proliferator activated receptor gamma2 (PPARgamma2) Pro12Ala variant: lack of association with type 2 diabetes in obese and non obese Tunisian patients. Diabetes Metab. 2005; 31(2): 119- 123. https://doi.org/10.1016/S1262-3636(07)70177-5
Meshkani R, Taghikhani M, Larijani B, et al. Pro12Ala polymorphism of the peroxisome proliferator- activated receptor- gamma 2(PPARgamma-2) gene is associated with greater insulin sensitivity and decreased risk of type 2 diabetes in an Iranian population. Clin Chem Lab Med. 2007; 45(4): 477- 482. https://doi.org/10.1515/CCLM.2007.095 PMid:17439324
Thorsby PM, Midthjell K, Gjerlaugsen N, et al. Comparison of genetic risk in three candidate genes (TCF7L2, PPARG, KNCJ11) with traditional risk factors for type 2 diabetes in a population- based study_ the HUNT study. Scand J Clin Lab Invest. 2009; 69(2): 282- 287. https://doi.org/10.1080/00365510802538188 PMid:18972257
American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2010; 33 (Supplement 1): S62-S69. https://doi.org/10.2337/dc10-S062 PMid:20042775 PMCid:PMC2797383
Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem. 1969; 9(6):24-25. https://doi.org/10.1177/000456326900600108
Hamann A, Munzberg H, Buttron P, et al. Missense variants in the human peroxisome proliferator- activated receptor-g2 gene in lean and obese subjects. Eur J Endocrinol. 1999; 141: 90- 92. https://doi.org/10.1530/eje.0.1410090 PMid:10407229
Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index, and improved insulin sensitivity. Nat Genet. 1998; 20(3):284–287. https://doi.org/10.1038/3099 PMid:9806549
Ringel J, Engeli S, Distler A, Sharma AM. Pro12Ala missense mutation of the peroxisome proliferator activated receptor gamma and diabetes mellitus. Biochem Biophys Res Commun. 1999; 254(2): 450- 453. https://doi.org/10.1006/bbrc.1998.9962 PMid:9918859
Mancini FP, Vaccaro O, Sabatino L, et al. Pro12Ala substitution in the peroxisome proliferator- activated receptor- γ2 is not associated with type 2 diabetes. Brief genetic report. Diabetes. 1999; 48: 1466- 1468. https://doi.org/10.2337/diabetes.48.7.1466 PMid:10389855
Dnawati CW, Nagata M, Moriyama H, et al. A possible association of Pro12Ala polymorphism in peroxisome proliferator- activated receptor gamma2 gene with obesity in native Javanese in Indonesia. Diabetes Metab Res Rev. 2005; 21(5): 465- 469. https://doi.org/10.1002/dmrr.543 PMid:15739197
Badii R, Bener A, Zirie M, et al. Lack of association between the Pro12Ala polymorphism of the PPAR-γ2 gene and type 2 diabetes mellitus in the Qatari consanguineous population. Acta Diabetol. 2008; 45: 15- 21. https://doi.org/10.1007/s00592-007-0013-8 PMid:17805473
Ghoussaini M, Meyre D, Lobbens S, et al. Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French Population. BMC Med Genet. 2005; 6: 11. https://doi.org/10.1186/1471-2350-6-11 PMid:15784141 PMCid:PMC1084346
Sanghera DK, Demirci FY, Been L, et al. PPARG and ADIPOQ gene polymorphisms increase type 2 diabetes mellitus risk in Asian Indian Sikhs: Pro12Ala still remains as the strongest predictor. Metabolism. 2010; 59: 492–501. https://doi.org/10.1016/j.metabol.2009.07.043 PMid:19846176 PMCid:PMC2843807
Ho JS, Germer S, Tam CH, et al. Association of the PPARG Pro12Ala polymorphism with type 2 diabetes and incident coronary heart disease in a Hong Kong Chinese population. Diabetes Res Clin Pract. 2012; 97(3): 483- 491. https://doi.org/10.1016/j.diabres.2012.03.012 PMid:22515931
De Pablos-Velasco PL, MartÃnez-MartÃn FJ, RodrÃguez-Pérez F, et al. Prevalence and determinants of diabetes mellitus and glucose intolerance in a Canarian Caucasian population: Comparison of the 1997 ADA and the 1985 WHO criteria. The Guia study. Diabet Med. 2001; 18: 235- 341. https://doi.org/10.1046/j.1464-5491.2001.00451.x PMid:11318846
Mori H, Ikegami H, Kawaguchi Y, et al. The Pro12→ Ala substitution in PPAR γ is associated with resistance to development of diabetes in the general population, possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes. 2001; 50: 891- 894. https://doi.org/10.2337/diabetes.50.4.891 PMid:11289058
Memisoglu A, Hu FB, Hankinson SE, et al. Prospective study of the association between the proline to alaninee codon 12 polymorphism in the PPAR gamma gene and type 2 diabetes. Diabetes Care. 2003; 26: 2915-2917. https://doi.org/10.2337/diacare.26.10.2915 PMid:14514601
Rodriguez- Esparragon FJ, Rodriguez- Perez JC, Macias- Reyes A, Alamo-Santana F. Peroxisome proliferator- activated receptor- gamma2 Pro12Ala and endothelial nitric acid synthase-4a/b gene polymorphisms are associated with essential hypertension. J Hypertens. 2003; 21: 1649- 1655. https://doi.org/10.1097/00004872-200309000-00013 PMid:12923396
Wang X, Liu J, Ouyang Y, et al. The association between the Pro12Ala variant of the PPARγ2 and Type 2 diabetes mellitus and obesity in a Chinese population. Plos One. 2013 (e71985); 8(8):1-6.
Altschuler D, Hirschhorn JN, Klannenmark M, Lindgren CM, Vohl M. The common PPAR Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000; 26: 76- 80. https://doi.org/10.1038/79216 PMid:10973253
Evans D, de Heer J, Hagemann C, et al. Association between the P12A and c1431t polymorphisms in the peroxisome proliferator activated receptor gamma (PPAR gamma) gene and type 2 diabetes. Exp Clin Endocrinol Diabetes. 2001; 109: 151-154. https://doi.org/10.1055/s-2001-14838 PMid:11409297
Lindi VI, Uusitupa MI, Lindstrom J, et al. Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes. 2002; 51: 2581-2586. https://doi.org/10.2337/diabetes.51.8.2581 PMid:12145174
Malecki MT, Frey J, Klupa T, et al. The Pro12Ala polymorphism of PPARgamma2 gene and susceptibility to type 2 diabetes mellitus in a Polish population. Diabetes Res Clin Pract. 2003; 62: 105-111. https://doi.org/10.1016/S0168-8227(03)00164-5
Stefan N, Fritsche A, Haring HU, Stumvoli M. Effects of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of the peroxisome proliferator- activated receptor- gamma2 gene. Diabetes. 2001; 50: 1143- 1148. https://doi.org/10.2337/diabetes.50.5.1143 PMid:11334419
Franks PW, Luan J, Browne PO, et al. Does peroxisome proliferator- activated receptor gamma genotype (Pro12Ala) modify the association of physical activity and dietary fat with fasting insulin level? Metabolism. 2004; 53: 11- 16. https://doi.org/10.1016/j.metabol.2003.08.005 PMid:14681835
Mattevi VS, Zembrzuski VM, Hutz MH. Effects of a PPARG gene variant on obesity characteristics in Brazil. Braz J Med Biol Res. 2007; 40(7): 927- 932. https://doi.org/10.1590/S0100-879X2006005000114 PMid:17653445
World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation (WHO Technical Report Series 894), 2000.
Chang CJ, Wu CH, Chang CS, et al. Low body mass index but high percent body fat in Taiwanese subjects: implications of obesity cutoffs. Int J Obesity. 2003; 27: 253- 259. https://doi.org/10.1038/sj.ijo.802197 PMid:12587007
Wildman RP, Gu D, Reynolds K, Duan X, He J. Appropriate body mass index and waist circumstances cutoffs for categorization of overweight and central adiposity among Chinese adults. Am J Clin Nutr. 2004; 80: 1129- 1136. https://doi.org/10.1093/ajcn/80.5.1129 PMid:15531658
Lindi V, Sivenius K, Niskanen L, Laakso M, Uusitupa M. Effect of the Pro12Ala polymorphism of the PPAR-gamma2 gene on long-term weight change in Finnish non-diabetic subjects. Diabetologia. 2001; 44: 925. https://doi.org/10.1007/s001250100558 PMid:11508283
Douglas JA, Edros MR. The peroxisome proliferator- activated receptor-γ2 Pro12Ala variant. Association with type 2 diabetes and trait differences. Diabetes. 2001; 50: 886- 890. https://doi.org/10.2337/diabetes.50.4.886 PMid:11289057
Stefanski A, Majkowska L, Ciechanowicz A, et al. Association between the Pro12Ala variant of the peroxisome proliferator- activated receptor- gamma 2 gene and increased 24-h diastolic blood pressure in obese patients with type II diabetes. J Human Hypertens. 2006; 20: 684- 692. https://doi.org/10.1038/sj.jhh.1002040 PMid:16625233
Sugawara A, Takeuchi K, Uruno A, et al. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator- activated receptor-γ in vascular smooth muscle cells. Endocrinology. 2001; 142: 3125- 3134. https://doi.org/10.1210/endo.142.7.8272 PMid:11416035
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0